If we assume either a higher price point (e.g. because of greater reduction in downstream hospitalization and other costs), a larger percentage of patients that could be impacted, or a broader market opportunity (e.g. reaching into markets like Russia, China, Latin America, India or other areas of the world) then this number quickly escalates.